Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
University of California, San Francisco National Institute of Allergy and Infectious Diseases (NIAID) |
---|---|
Information provided by: | University of California, San Francisco |
ClinicalTrials.gov Identifier: | NCT00187512 |
SCOPE is an observational, prospective study of HIV-1 infected volunteers designed to provide a specimen bank of samples with carefully characterized clinical data. SCOPE specimens will be used to examine multiple questions involving virologic, immunologic, and host factors involved in HIV-1 infection, progression, non-progression, response to treatment, control of HIV-1 virus, and evolution of drug resistance.
Condition |
---|
HIV Infections |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era |
Plasma, serum, PMBCs, saliva
Estimated Enrollment: | 2000 |
Study Start Date: | March 2000 |
Estimated Study Completion Date: | December 2014 |
SCOPE is an observational, prospective study of HIV-1 infected volunteers designed to provide a specimen bank of samples with carefully characterized clinical data. Samples from SCOPE will be used to examine:
Enrolled subjects are seen at San Francisco General Hospital every four months for a detailed interview, saliva collection, and blood draw. Baseline visits take approximately one hour, follow up visits take approximately 20-40 minutes. No personal identifiers are used for specimen bank samples.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
The study is open to eligible subjects who are able to perform study visits at San Francisco General Hospital or the San Francisco VA Medical Center.
Inclusion Criteria:
SCOPE is currently recruiting HIV-1 infected subjects with any of the following criteria:
Exclusion Criteria:
Contact: Rebecca Hoh, M.S. | 415-476-4082 ext 139 | rhoh@php.ucsf.edu |
Contact: Marcia Smith, B.S. | 415-476-4082 ext 118 | masmith@php.ucsf.edu |
United States, California | |
San Francisco General Hospital | Recruiting |
San Francisco, California, United States, 94110 | |
Contact: Rebecca Hoh, M.S. 415-476-4082 ext 139 rhoh@php.ucsf.edu | |
Contact: Marcia Smith, B.S. 415-476-4082 ext 118 masmith@php.ucsf.edu | |
Principal Investigator: Steven G. Deeks, M.D. |
Principal Investigator: | Steven G. Deeks, M.D. | University of California, San Francisco |
Responsible Party: | University of California, San Francisco ( Steven Deeks, Professor of Medicine ) |
Study ID Numbers: | H8211-17887-08 |
Study First Received: | September 13, 2005 |
Last Updated: | February 23, 2009 |
ClinicalTrials.gov Identifier: | NCT00187512 History of Changes |
Health Authority: | United States: Institutional Review Board |
HIV Antiretroviral Agents Drug Resistance, Multiple Long Term Non Progression Long Term Non Progressor |
Elite Suppression Elite Suppressor Natural History Observational |
Virus Diseases Sexually Transmitted Diseases, Viral Anti-Retroviral Agents HIV Infections Sexually Transmitted Diseases |
Acquired Immunodeficiency Syndrome Retroviridae Infections Immunologic Deficiency Syndromes Protease Inhibitors |
RNA Virus Infections Sexually Transmitted Diseases, Viral Slow Virus Diseases Molecular Mechanisms of Pharmacological Action Immune System Diseases Acquired Immunodeficiency Syndrome Enzyme Inhibitors Infection |
Pharmacologic Actions Immunologic Deficiency Syndromes Protease Inhibitors Virus Diseases HIV Infections Sexually Transmitted Diseases Lentivirus Infections Retroviridae Infections |